BMS-986453 / BMS - LARVOL DELTA

BMS-986453, a Dual-Targeting BCMAxGPRC5D Autologous CAR T Cell Therapy in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results From a Phase 1 Trial (IMS 2026) - P1 | "BMS-986453 is an investigational, dual-targeting BCMA×GPRC5D CAR T cell therapy. BMS-986453 demonstrated favorable safety and efficacy in pts with RRMM."

CAR T-Cell Therapy • Clinical • First-in-human • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

Development of BMS-986453, a Dual-Targeting BCMAxGPRC5D Chimeric Antigen Receptor (CAR) for the Treatment of Multiple Myeloma (IMS 2026) - P1 | "The objective was to design, optimize, and evaluate dual-targeting BCMA×GPRC5D CAR T cell therapy for MM. High BCMA and GPRC5D expression in patients with ≥3 prior LOT confirms their suitability as dual-targeting CAR antigens. The loop tandem design was superior to bicistronic or linear tandem approaches, and the resulting CAR demonstrated potent dual-antigen activity in preclinical studies. These data supported advancement of BMS-986453 into clinical development, where early phase 1 results (NCT06153251) indicate a highly functional and potent CAR capable of effectively targeting BCMA and GPRC5D in patients."

First-in-human • IO biomarker • Hematological Malignancies • Multiple Myeloma • GPRC5D

DEVELOPMENT OF BMS-986453, A DUAL-TARGETING BCMA×GPRC5D CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF MULTIPLE MYELOMA (EHA 2026) - P1 | "Aims To design, optimize, and evaluate the activity of dual-targeting BCMA×GPRC5D CAR T cell therapy for the treatment of MM. DJ and RS contributed equally as co-senior authors. Figure 1"

First-in-human • IO biomarker • Hematological Malignancies • Multiple Myeloma • GPRC5D

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Susan Bal | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2043 ➔ Dec 2041 | Trial primary completion date: Jan 2028 ➔ Dec 2031

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Susan Bal

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial completion date: Nov 2027 ➔ May 2030 | Trial primary completion date: Nov 2027 ➔ May 2030

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology